Publications

Phase Ii, Multicenter, Single-Arm Trial of Eribulin as First-Line Therapy for Patients With Aggressive Taxane-Pretreated Her2-Negative Metastatic Breast Cancer: The Meribel Study

AuthID
P-00Q-4Y2

Author(s)

Ortega, V

Anton, A

Garau, I

Afonso, N

Calvo, L

Fernandez, Y

Martinez Garcia, M

Blanco, E

Zamora, P

Garcia, M

Juan Illarramendi, JJ

Rodrguez Sanchez, CAR

Sampayo, M

Aguirre, E

Manuel Perez Garcia, JM

Cortes, J

Llombart Cussac, A

Document Type

Article

Year published

2019

Published

in CLINICAL BREAST CANCER, ISSN: 1526-8209

Volume: 19, Issue: 2, Pages: 105-112 (8)

Indexing

Wos^®

Scopus^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.clbc.2018.12.012

SCOPUS: 2-s2.0-85060147511

Wos: WOS:000462167800019

Source Identifiers

ISSN: 1526-8209

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Phase Ii, Multicenter, Single-Arm Trial of Eribulin as First-Line Therapy for Patients With Aggressive Taxane-Pretreated Her2-Negative Metastatic Breast Cancer: The Meribel Study

Useful Links

Get Help

Federated Authentication (Click on the image)

Phase Ii, Multicenter, Single-Arm Trial of Eribulin as First-Line Therapy for Patients With Aggressive Taxane-Pretreated Her2-Negative Metastatic Breast Cancer: The Meribel Study

Useful Links

Get Help